论文部分内容阅读
目的观察参麦注射液辅助治疗急性心肌梗死的临床疗效及安全性。方法将72例急性心肌梗死患者随机分为对照组35例和试验组37例。对照组予以吸氧、抗凝、抗血小板等治疗;试验组在对照组治疗的基础上,予以静脉滴注参麦注射液20 mL qd。2组患者均治疗2周。比较2组患者的临床疗效和药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为89.19%(33/37例)和71.43%(25/35例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的左心室射血分数(LVEF)分别为(72.16±16.44)%,(58.43±20.06)%;E峰值分别为(88.40±8.89),(68.19±6.87)cm·s~(-1);E/A值分别为(1.27±0.13),(0.98±0.10),差异均有统计学意义(P<0.05)。治疗后,试验组和对照组的A峰值分别为(69.61±7.03),(69.58±7.01)cm·s~(-1),差异无统计学意义(P>0.05)。治疗期间,试验组发生的药物不良反应有口干、过敏、恶心,对照组发生的药物不良反应有口干、过敏、头痛。试验组和对照组的药物不良反应率分别为13.51%和8.57%,差异无统计学意义(P>0.05)。结论参麦注射液辅助治疗急性心肌梗死有很好的临床疗效,且不增加药物不良反应的发生率。
Objective To observe the clinical efficacy and safety of Shenmai injection in the treatment of acute myocardial infarction. Methods Seventy-two patients with acute myocardial infarction were randomly divided into control group (35 cases) and experimental group (37 cases). The control group was treated with oxygen, anticoagulation and antiplatelet therapy. On the basis of the control group, the experimental group was given intravenous infusion of 20 mg qd of Shenmai injection. Two groups of patients were treated for 2 weeks. The clinical efficacy and adverse drug reactions in two groups were compared. Results After treatment, the total effective rates of the experimental group and the control group were 89.19% (33/37 cases) and 71.43% (25/35 cases) respectively, the difference was statistically significant (P <0.05). After treatment, left ventricular ejection fraction (LVEF) of the experimental group and control group were (72.16 ± 16.44)% and (58.43 ± 20.06)%, respectively; the peak values of E were 88.40 ± 8.89 and 68.19 ± 6.87 cm s ~ (-1); E / A values were (1.27 ± 0.13) and (0.98 ± 0.10) respectively, the differences were statistically significant (P <0.05). After treatment, the A peak values in the test group and the control group were (69.61 ± 7.03) and (69.58 ± 7.01) cm · s -1, respectively, with no significant difference (P> 0.05). During the treatment, adverse drug reactions occurred in the test group were dry mouth, allergies, nausea, adverse reactions occurred in the control group of dry mouth, allergies, headache. Adverse drug reaction rates in the experimental and control groups were 13.51% and 8.57%, respectively, with no significant difference (P> 0.05). Conclusion Shenmai injection adjuvant treatment of acute myocardial infarction has a good clinical efficacy, and does not increase the incidence of adverse drug reactions.